Last updated on July 2018

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study

Brief description of study

The main purpose of this study is to determine the safety and efficacy of the study drug galcanezumab in participants 6 to 17 years of age with episodic migraine.

Clinical Study Identifier: TX208045

Find a site near you

Start Over